MARKET

RPTX

RPTX

Repare Therapeutics Inc.
NASDAQ
1.360
0.000
0.00%
Pre Market: 1.360 0 0.00% 04:50 05/12 EDT
OPEN
1.370
PREV CLOSE
1.360
HIGH
1.410
LOW
1.350
VOLUME
30
TURNOVER
0
52 WEEK HIGH
4.290
52 WEEK LOW
0.8900
MARKET CAP
58.33M
P/E (TTM)
-0.6811
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RPTX last week (0505-0509)?
Weekly Report · 42m ago
Weekly Report: what happened at RPTX last week (0428-0502)?
Weekly Report · 05/05 09:17
LifeSci Capital Keeps Their Hold Rating on Repare Therapeutics (RPTX)
TipRanks · 05/01 16:15
Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics
TipRanks · 05/01 11:29
Repare Therapeutics Out-Licenses Its Discovery Platforms To DCx Biotherapeutics; Will Receive $4M Upfront And 9.99% Common Equity Position In DCx And Is Eligible For Milestone Payments And Royalties
Benzinga · 05/01 11:14
REPARE THERAPEUTICS ANNOUNCES OUT-LICENSING OF ITS DISCOVERY PLATFORMS TO DCX BIOTHERAPEUTICS
Reuters · 05/01 11:00
Is Repare Therapeutics (NASDAQ:RPTX) In A Good Position To Deliver On Growth Plans?
Simply Wall St · 04/29 10:45
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry
Simply Wall St · 04/29 10:31
More
About RPTX
More
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Recently
Symbol
Price
%Change

Webull offers Repare Therapeutics Inc stock information, including NASDAQ: RPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPTX stock methods without spending real money on the virtual paper trading platform.